C. Michael Gibson, MD

C. Michael Gibson M.S., M.D., pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times), the TIMI myocardial perfusion grade (cited 1,089 times).

Gibson is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.

The institutes have led over 1,000 studies, published 5,500 manuscripts in the peer review literature (including 144 in the New England Journal) and have led 100 FDA submissions from their network of 7,000 sites worldwide. Since 2014, he has consistently been ranked as one of the world’s most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 148,000 times, and he has an H index of 134 and an i10-index of 549.

Dr. Gibson is a practicing interventional cardiologist who has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians.

Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 30,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He is currently leading the first large “Virtual” randomized trial which uses apps and the internet to eliminate “bricks and mortar” and is being conducted at 1% of the usual cost. The HEARTLINE trial of the Apple watch will enroll up to 180,000 patients and is one of the largest randomized patient trials in history. Gibson and his team will be operationalizing many of the trial efforts of Milvexian, a Factor Xi inhibitor across a variety of disease states.

For years, Gibson has been chosen as one of Boston’s Top Doctors & U.S. News & World Report also lists Gibson as one of America’s top doctors.

Dr. Gibson obtained his BS, MS, and MD degrees at the University of Chicago where he was a Phi Beta Kappa and AOA graduate, and was a starting half back. He then went on to do his internship, residency and chief residency at the Brigham and Women’s Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School.

Gibson founded WikiDoc.org and WikiPatient.org, widely viewed open source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org and has conducted >2,600 TV / video interviews. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls.

Gibson is an at large member of the FDA’s cardiorenal panel having served as a standing member from 2017 to 2021.

He is an accomplished artists whose work is held in numerous collections.


Dr. Gibson follows the conflict of interest policies set forth by Harvard Medical School and the Beth Israel Deaconess Medical Center. The Baim Institute follows the same conflict of interest policies as Harvard Medical School and Beth Israel Deaconess Medical Center. The dates of payments are based on the date payment was received (on a cash basis) rather than the date of billing (accrual basis).

Executive Position

Chief Executive Office, Baim Institute for Clinical Research

Present Research/Grant Funding (within the last year)

Ongoing: CSL Behring; Janssen Pharmaceuticals; Johnson & Johnson Corporation; SCAD Alliance;


Amgen, Angel/Avertix Medical Corporation, AstraZeneca, Bayer Corporation, Beren Therapeutics, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Bristol-Myers Squibb, Cadrenal Therapeutics, Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, DCRI, Esperion, EXCITE International ($0 Received), Faraday Pharmaceuticals, Fortress Biotech, HeartFlow, Gilead Sciences, Inc., Intellia Therapeutics, Janssen, Pharmaceuticals, Johnson & Johnson Corporation, Lumanity, MashUp MD, MD Magazine, MJHealth, NovoNordisk, Pfizer, PLxPharma, SCAI, Solstic Health/New Amsterdam Pharma, Somahlution/Marizyme, Synergia Medical, Vectura, Web MD, Women as One

For Trials that Dr. Gibson actively serves as PI of and receives research grant support on an ongoing basis, there is less than $25,000 per year in consulting monies received per the Harvard, BIDMC, Baim policies.


Absolutys, Dyad Medical, Gererable, Flow Therapy Fortress Biotech, Heart Beam, nference

Royalties as a Contributor

UpToDate in Cardiovascular Medicine

Spouse conflicts of interests (Employee of Boston Clinical Research Institute)

Amgen, Angel/Avertix Medical Corporation, AstraZeneca, Bayer, Beren Therapeutics, Bioclinica, Boehringer Ingelhim, Boston Scientific, Cadrenal Therapeutics, Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, DCRI, Esperion, EXCITE International ($0 Received), Faraday Pharmaceuticals, Fortress Biotech, Gilead Sciences, Inc., Heart Flow, Inari, Intellia Therapeutics, Janssen, Johnson and Johnson, Lumanity, MashUp MD, MD Magazine, Merck,LLC, MjHealth, NovoNordisk, Pfizer, PhaseBio, Revance Therapeutics, Samsung, SCAI, SFJ, Solstic Health/New Amsterdam Phara, Somahlution/Marizyme, Vectura, Woman as One

Baim- and Baim-affiliated faculty members disclose the conflicts of interest for the Baim Institute which can be viewed here.